Metropolitan Life Insurance Co. NY decreased its stake in Hologic, Inc. (NASDAQ:HOLX) by 18.1% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 40,483 shares of the medical equipment provider’s stock after selling 8,947 shares during the period. Metropolitan Life Insurance Co. NY’s holdings in Hologic were worth $1,609,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently made changes to their positions in HOLX. Quantum Capital Management purchased a new position in Hologic in the 2nd quarter worth approximately $431,000. Marshall Wace LLP purchased a new position in Hologic in the 2nd quarter worth approximately $4,086,000. Sterling Capital Management LLC grew its stake in Hologic by 1.2% in the 2nd quarter. Sterling Capital Management LLC now owns 1,482,563 shares of the medical equipment provider’s stock worth $58,932,000 after buying an additional 18,120 shares in the last quarter. Morgan Stanley grew its stake in Hologic by 68.8% in the 2nd quarter. Morgan Stanley now owns 943,536 shares of the medical equipment provider’s stock worth $37,505,000 after buying an additional 384,676 shares in the last quarter. Finally, Capital Fund Management S.A. purchased a new position in Hologic in the 2nd quarter worth approximately $2,905,000. 98.65% of the stock is currently owned by institutional investors and hedge funds.
In related news, insider Benjamin Jordan Cohn sold 3,437 shares of the company’s stock in a transaction on Wednesday, September 19th. The shares were sold at an average price of $41.50, for a total transaction of $142,635.50. Following the completion of the sale, the insider now directly owns 16,520 shares in the company, valued at approximately $685,580. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Sally Crawford sold 13,257 shares of the company’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $39.54, for a total transaction of $524,181.78. Following the sale, the director now owns 167,701 shares of the company’s stock, valued at $6,630,897.54. The disclosure for this sale can be found here. Insiders have sold a total of 47,661 shares of company stock valued at $1,927,174 over the last quarter. 0.88% of the stock is currently owned by company insiders.
Shares of HOLX traded up $0.70 during mid-day trading on Friday, reaching $40.04. The company’s stock had a trading volume of 2,086,350 shares, compared to its average volume of 2,324,738. Hologic, Inc. has a 52 week low of $35.10 and a 52 week high of $45.09. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.99 and a current ratio of 1.29. The firm has a market cap of $11.15 billion, a price-to-earnings ratio of 19.72, a PEG ratio of 2.01 and a beta of 0.67.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Tuesday, July 31st. The medical equipment provider reported $0.58 EPS for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.02. Hologic had a negative net margin of 2.47% and a positive return on equity of 22.18%. The company had revenue of $824.00 million during the quarter, compared to analyst estimates of $800.14 million. As a group, equities research analysts predict that Hologic, Inc. will post 2.24 earnings per share for the current year.
A number of research firms have commented on HOLX. Jefferies Financial Group reissued a “buy” rating and issued a $50.00 price target on shares of Hologic in a research note on Wednesday, August 1st. Canaccord Genuity cut their price target on shares of Hologic from $42.00 to $41.00 and set a “hold” rating for the company in a research note on Tuesday, August 14th. TheStreet cut shares of Hologic from a “b-” rating to a “c+” rating in a research note on Wednesday, September 5th. BidaskClub upgraded shares of Hologic from a “sell” rating to a “hold” rating in a report on Saturday, September 15th. Finally, Morgan Stanley lowered their price objective on shares of Hologic from $47.00 to $44.00 and set an “equal weight” rating for the company in a report on Thursday. One analyst has rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $44.47.
Hologic Company Profile
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
See Also: Outstanding Shares
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.